dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pistilli, Barbara |
dc.contributor.author | Braña Garcia, Irene |
dc.contributor.author | Shapiro, G. I. |
dc.contributor.author | Trigo, José Manuel |
dc.contributor.author | Boni, Valentina |
dc.contributor.author | Moreno, Victor |
dc.date.accessioned | 2022-11-10T07:23:09Z |
dc.date.available | 2022-11-10T07:23:09Z |
dc.date.issued | 2022-10 |
dc.identifier.citation | Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, et al. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 2022 Oct;7(5):100571. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/8428 |
dc.description | Càncer de mama; Lurbinectedina; Taxa de resposta |
dc.description.sponsorship | This work was supported by PharmaMar S.A, including partial funding by grants from the Centro para el Desarrollo Tecnológico IndustrialCentro para el Desarrollo Tecnológico Industrial (CDTI) during the conduct of the study (grant number IDI-20150006). VS is supported by NIH [grant number R01CA242845]. MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas [grant number RP1100584], the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy [grant number 1U01 CA180964], NCATS [grant number UL1 TR000371] (Center for Clinical and Translational Sciences) and the MD Anderson Cancer Center Support [grant number P30 CA016672]. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;7(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /therapeutic use |
dc.title | Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2022.100571 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2022.100571 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Boni V] START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Pistilli B] Gustave Roussy, Villejuif, France. [Braña I] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Shapiro GI] Dana-Farber Cancer Institute, Boston, USA. [Trigo J] Hospital Universitario Virgen De La Victoria, IBIMA, Málaga, Spain. [Moreno V] START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain |
dc.identifier.pmid | 36037567 |
dc.identifier.wos | 000861347400008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |